Mechanical Cooling System — MCS-1

Vitrification without
liquid nitrogen

The first closed-system vitrification device powered by a Stirling engine cold finger. Reaches −221 °C (52 K) mechanically — eliminating LN₂ dependency, contamination risk, and the vapor layer problem that makes every open carrier inherently inconsistent.

−221°C
working temperature (52 K)
2,500
K/min cooling rate
0
LN₂ required
52
supporting studies (SSV)
US
12,588,674 B2 — granted
100%
closed system
Request briefing View patent →
52 K −221°C
Sterling cold finger
Copper thermal bridge
T = 52 K / −221°C
The LN₂ Problem

Every current system
depends on an inherently
unstable interface

Liquid nitrogen boils at −196 °C. The moment a warm carrier contacts it, the Leidenfrost effect creates an insulating vapor layer — making cooling rates variable, uncontrolled, and impossible to standardize across clinics.

  • ∆T
    Leidenfrost vapor layer
    The boiling LN₂ forms a gaseous insulating layer between the carrier and the cryogen, reducing and randomizing actual cooling rate — the exact parameter that determines vitrification quality.
  • ☣
    Cross-contamination risk
    Open LN₂ dewars are shared liquid environments. Viruses and bacteria survive in LN₂ indefinitely. No open-carrier system can guarantee biological isolation between samples.
  • ⚠
    Supply chain dependency
    Every IVF laboratory globally depends on continuous LN₂ supply for storage and vitrification. Shortage events, delivery failures, or storage loss are irreversible for patient samples.
  • ≠
    Inter-lab irreproducibility
    Carrier geometry, LN₂ volume, technique, and local altitude all affect vapor dynamics. Two labs using the same protocol achieve different outcomes — a fundamental reproducibility failure.
Cooling rate comparison — open LN₂ vs mechanical
−221°C −196°C −100°C 0°C 0s 5s 10s Leidenfrost vapor zone variable, uncontrolled insulation VitriGen (mechanical) Open LN₂
The VitriGen Principle

A Stirling engine
replaces the dewar

VitriGen uses a free-piston Stirling cryocooler to drive a copper cold finger to 52 K. The sample contacts only the cold finger — never an open liquid cryogen. Cooling rate, contact geometry, and endpoint temperature are all mechanically defined and reproducible.

01
Stirling cycle generates cold
A free-piston Stirling engine runs continuously, driving the cold head to 52 K (−221 °C). No cryogen is consumed. The cold finger is always at operating temperature — no cooldown wait time.
02
Sample loads via sealed carrier
The oocyte or embryo on its carrier is introduced into the sealed loading chamber. Contact with the cold finger surface initiates vitrification — controlled, closed, and contamination-free.
03
2,500 K/min cooling rate — mechanically defined
Heat transfer through the copper cold finger is direct and solid-state. There is no vapor layer to randomize the interface. Every sample in every lab experiences the same defined thermal event.
04
Transfer to closed LN₂ storage
After vitrification, the carrier is sealed and transferred to closed LN₂ storage (standard goblet/cane). The VitriGen system makes the most hazardous step — the open cooling step — LN₂-free.
Sterling cryocooler — simplified cross-section FREE-PISTON STIRLING ENGINE HOT COLD REG COLD FINGER — 52 K SAMPLE ZONE +20°C −221°C sealed chamber
52 K / −221°C cold head temperature
~2,500 K/min cooling rate
OFC Copper cold finger material
0 mL LN₂ consumed
Intellectual property

Granted US patent
12,588,674 B2

Granted March 31, 2026 to inventors Daniel A. Nemeth, Lee L. Nemeth along with Rod DaSilva. Claims cover the use of a mechanical cryocooler (Stirling engine) to vitrify biological samples via a copper cold finger — a categorically new claim space with no prior art overlap.

US 12,588,674 B2 — GRANTED
FIG. 1 — System Overview Claim 1
DISPLAY STERLING ENGINE SAMPLE LOADING SHELF 1 2 3 4 ①Display ②Sterling unit ③Cold finger ④Sample shelf
FIG. 2 — Cold Finger Detail Claim 3–5
WARM END ~20°C REGENERATOR COLD HEAD 52 K +20°C 52 K tip
FIG. 3 — Contamination Analysis Claim 8
OPEN LN₂ vapor shared environment cross-contamination VITRIGEN isolated contact zero contamination ✕ biological risk ✓ sterile isolated
Scientific Validation

52 studies confirm
the SSV principle

The science behind solid-surface vitrification (SSV) — the contact cooling method at the heart of VitriGen — has been validated across 52 independent peer-reviewed studies. The key finding: direct solid contact outperforms LN₂ immersion for cooling rate and outcomes.

52
peer-reviewed studies
Independent research validating solid-surface vitrification as superior to open LN₂ methods across survival, fertilization, and blastocyst development rates.
2,500
K/min — controlled cooling rate
The Sterling cold finger delivers a reproducible cooling event. Unlike LN₂ vapor-layer dynamics, this rate does not vary with technique, operator, or altitude.
0
open LN₂ exposure events
Every vitrification run with VitriGen produces zero open-cryogen exposure events. The entire phase transition occurs within the sealed mechanical system.
SSV meta-analysis // 2021 Oocyte survival
Solid-surface vitrification consistently achieved oocyte survival rates statistically equivalent to or exceeding LN₂-immersion methods, with significantly lower variance between operators — confirming that eliminating the vapor-layer interface is the key reproducibility driver.
Cryoloop vs SSV comparison Blastocyst development
Direct solid-contact groups demonstrated improved blastocyst development rates at 120 hours post-warming, attributed to more consistent vitrification kinetics versus the stochastic vapor-layer insulation inherent to open LN₂ methods.
Contamination risk modeling Biosafety
Pathogen transmission studies confirm that viruses including HIV, HCV, and HPV remain viable in LN₂ indefinitely. Closed mechanical cooling eliminates the shared-liquid contamination vector entirely — a risk that open systems cannot engineer away.
Cryologic head-to-head // ESHRE Clinical equivalence
Comparative studies between SSV-based systems and Cryologic/Vitrolife Rapid-i (the leading closed LN₂ system) showed equivalent clinical outcomes — confirming the method is ready for clinical deployment without outcome compromise.

Beyond IVF — Stem Cell & Cell-Therapy Applications

The same LN₂ dependency that burdens IVF labs is present in stem cell and cell-therapy biobanks. Cryoprotectant formulations for iPSCs and hematopoietic cells require the same ultralow temperatures — and carry the same contamination, supply chain, and reproducibility risks. A mechanically defined cold finger with no open cryogen is relevant to both markets: reproductive medicine and cell therapy share the identical physics problem.

Competitive positioning

VitriGen is a
different category

Today's market splits between open LN₂ (Cryotec, Cryoloop) and closed LN₂ (Rapid-i, CryoTip). All four remain LN₂-dependent. VitriGen is the only system that eliminates LN₂ from the vitrification event entirely.

Feature Open LN₂
Cryotec, Cryoloop		 Closed LN₂
Rapid-i, CryoTip		 VitriGen MCS-1New category
LN₂ at vitrification ✕ direct immersion ~ sealed, still LN₂ ✓ zero LN₂
Leidenfrost effect ✕ present, uncontrolled ✕ present at contact ✓ physically impossible
Cross-contamination risk ✕ shared dewar ~ reduced, not zero ✓ zero — no shared cryogen
Cooling rate ~2,000–4,000 K/min (variable) ~1,500–3,000 K/min (variable) ~2,500 K/min (defined)
Reproducibility ✕ operator-dependent ~ moderate ✓ mechanically defined
LN₂ supply dependency ✕ continuous supply ✕ continuous supply ✓ electricity only
Regulatory pathway Cleared (existing) Cleared (existing) 510(k) / De Novo (in progress)
IP protection — — US 12,588,674 B2 granted
Working temperature −196 °C (LN₂ boiling point) −196 °C (LN₂ boiling point) −221 °C (52 K)
Technical specifications — MCS-1

Precision engineering,
laboratory footprint

Cooling principle Free-piston Stirling cryocooler
Cold finger material Oxygen-free copper (OFC)
Working temperature 52 K (−221 °C)
Cooling rate ~2,500 K/min
Cooling medium None — solid contact only
Sample compatibility Oocytes, embryos (cleavage/blastocyst)
Carrier compatibility Standard SSV / Cryotec-type carriers
Power requirement 120V / 240V, 50–60 Hz
Form factor Mobile cart — lab-ready
Display Touchscreen — temperature, cycle status
Patent US 12,588,674 B2 (granted)
Regulatory status Pre-market (510k/De Novo pathway)
Stage Prototype validated — engaging production & clinical partners
MCS-1 — laboratory cart form factor 52.1 K READY STERLING UNIT SAMPLE LOADING ZONE STORAGE / UTILITIES cold finger
MCS-1 — mobile laboratory cart / prototype
Pipeline

What's next

VitriGen has cleared the hardest technical milestones: working prototype, operating temperature confirmed, patent granted. The path to clinical deployment is a production and regulatory sprint.

Completed
Milestone 1
Prototype & patent
Working prototype achieving 52 K on the cold finger confirmed. US patent 12,588,674 B2 granted. Sterling engine sourced and validated. Proof-of-concept vitrification runs completed.
Active
Milestone 2 — current
Production partner & pre-clinical validation
Seeking manufacturing partner for engineering pilot run (n=10 units). Parallel pre-clinical validation protocol with IVF partner laboratory — oocyte/embryo survival endpoints, cooling rate measurement, contamination assays.
Next
Milestone 3
510(k) / De Novo regulatory submission
FDA 510(k) or De Novo application based on pre-clinical data package. Predicate analysis ongoing — Rapid-i (Vitrolife) as primary comparator. Target: submission within 18 months of production partner close.
Target
Milestone 4
Clinical launch & licensing
Initial placement in partner IVF clinics under IDE or post-clearance. Parallel licensing discussions with major ART device manufacturers (Vitrolife, CooperSurgical, Igenomix). Target: first commercial placement within 36 months.

Interested in
VitriGen?

We're speaking with IVF laboratories, fertility equipment manufacturers, and strategic investors who understand the magnitude of the LN₂ dependency problem in reproductive medicine.

The global vitrification device market is projected to reach $1.1B by 2033 (9.5% CAGR), driven by the shift toward closed, contamination-controlled systems — with IVF clinics representing 71.8% of vitrification spend and Europe the largest regional market.

A full technical briefing package — including the patent, pre-clinical data, and competitive analysis — is available upon request.

@
Email
rod@ecryogenics.com
☎
Direct
+1 (203) 727-3405
⊞
Interested parties
IVF labs · Manufacturers · Strategic investors · Licensing partners
⚑
Patent on file
US 12,588,674 B2
Request a briefing

NDA available on request. All enquiries handled directly by the inventor.